Six novel peptides isolated from kenaf seed protein hydrolysates demonstrated strong ACE inhibitory activity up to 83.69%, with LYWSYLYN showing the best kinetic profile as a potential natural antihypertensive agent.
83.69%ACE inhibitory activity of the 2-5 kDa peptide fraction from kenaf seed protein hydrolysate
What the researchers found
Optimized hydrolysis of kenaf seed protein (65°C, pH 6.5, 2.25 hours, E/S ratio 0.03) achieved 55.28% degree of hydrolysis and 75.51% ACE inhibitory activity. The <2 kDa and 2-5 kDa peptide fractions showed the highest activity (82.27% and 83.69% respectively).
Six novel ACE-inhibitory peptides were identified from the 2-5 kDa fraction by QTOF LC-MS: LYWSYLYN, ALFYWVS, LLLHAL, AKSCVVFP, INPPSTTN, and WTIPTPS. Kinetic studies revealed LYWSYLYN had the highest Michaelis constant (Km) and maximum velocity (Vmax) values with the lowest inhibitor constant (Ki), confirming it as the most potent ACE inhibitor among the six peptides.
Why it matters
ACE inhibitor drugs are among the most prescribed medications for hypertension, but they can cause side effects like dry cough and angioedema. Food-derived bioactive peptides offer a potential natural complement or alternative. Kenaf seeds are an underutilized protein source, and identifying specific ACE-inhibitory peptides from them could support the development of functional foods, nutraceuticals, or novel antihypertensive agents from sustainable plant sources.
How the study worked
Kenaf seed protein was enzymatically hydrolyzed under conditions optimized by response surface methodology (RSM). The hydrolysates were fractionated by molecular weight. ACE inhibitory activity was measured for each fraction. Peptides in the most active fraction (2-5 kDa) were identified using Quadrupole-Time-of-Flight Liquid Chromatography-Mass Spectrometry (QTOF LC-MS). Molecular docking simulations modeled peptide-ACE interactions, and enzyme kinetic studies characterized the inhibition mechanisms.
What this study cannot tell us
All results are in vitro — the peptides have not been tested in animals or humans for actual blood pressure-lowering effects. Bioactive peptides may be degraded by gastrointestinal enzymes before reaching the bloodstream, so in vitro ACE inhibition may not translate to in vivo efficacy. The stability, bioavailability, and safety of these specific peptides are unknown. Molecular docking provides computational predictions that need experimental validation.
How to read the evidence
This is an in vitro laboratory study identifying and characterizing bioactive peptides. While the analytical chemistry and enzyme kinetics are rigorous, no in vivo or clinical data is presented, placing this at an early discovery stage.
When this study was published
Published in 2022, this represents current work in the food-derived bioactive peptide field. Whether these specific peptides have progressed to in vivo testing since publication is unknown.
The bigger picture
Food-derived ACE-inhibitory peptides are an active area of nutraceutical research, with peptides from milk, fish, soy, and other sources already studied extensively. This work expands the repertoire to kenaf seeds and uses a rigorous combination of optimization, mass spectrometry identification, molecular docking, and kinetic characterization — setting a high standard for bioactive peptide discovery. The identified peptides add to the growing library of plant-derived antihypertensive peptide candidates.
Questions still open
- Can these kenaf seed peptides survive gastrointestinal digestion and reach the bloodstream in active form?
- How does the ACE inhibitory potency of LYWSYLYN compare to established food-derived peptides like IPP and VPP from milk?
- Could these peptides be formulated into a functional food or supplement that demonstrates blood pressure reduction in clinical trials?
Common questions
What are ACE-inhibitory peptides and how could they lower blood pressure?
What is kenaf and could you eat these peptides in food?
Read the original research
Identification, molecular docking, and kinetic studies of six novel angiotensin-I-converting enzyme (ACE) inhibitory peptides derived from Kenaf (Hibiscus cannabinus L.) seed.
International journal of biological macromolecules, 220, 1512-1522
Citation
Zaharuddin, Nurul Dhania; Barkia, Ines; Wan Ibadullah, Wan Zunairah; Zarei, Mohammad; Saari, Nazamid. (2022). Identification, molecular docking, and kinetic studies of six novel angiotensin-I-converting enzyme (ACE) inhibitory peptides derived from Kenaf (Hibiscus cannabinus L.) seed.. International journal of biological macromolecules, 220, 1512-1522. https://doi.org/10.1016/j.ijbiomac.2022.09.142